<DOC>
	<DOCNO>NCT02166853</DOCNO>
	<brief_summary>Numerous trial support efficacy safety volatile anesthetic agent , namely inhalation sevoflurane dedicate device , sedation ICU patient . Several preclinical study show sevoflurane inhalation improve gas exchange decrease pulmonary systemic inflammation experimental model acute respiratory distress syndrome ( ARDS ) . The purpose prospective monocentric , randomize , control trial evaluate effect early 48-hour sevoflurane inhalation gas exchange inflammation patient ARDS .</brief_summary>
	<brief_title>Effects SEvoflurane Gas Exchange Inflammation Patients With ARDS ( SEGA Study )</brief_title>
	<detailed_description>BACKGROUND : Acute respiratory distress syndrome ( ARDS ) characterize hypoxemic respiratory failure lethal 30 60 % patient . Its pathophysiological landmark , diffuse alveolar damage , associate alveolar inflammation , epithelial injury alveolar fluid clairance impairment . Several preclinical study show early sevoflurane inhalation improve gas exchange , reduces alveolar edema attenuates pulmonary systemic inflammation experimental model ARDS . To date , clinical trial assess effect early sevoflurane inhalation ARDS patient . DESIGN NARRATIVE : The purpose prospective , randomize , control study evaluate effect 48-hour sevoflurane inhalation strategy gas exchange systemic pulmonary inflammation early phase ARDS . After inclusion , ICU patient moderate severe ARDS ( accord Berlin definition ARDS criterion ; JAMA 2010 ) randomize two group : - `` conventional group '' , intravenous sedation midazolam administer - `` sevoflurane group '' , patient inhale sevoflurane 48 hour-period , dedicate device Arterial blood gas analyze randomization 24 , 48 , 72 , 96 , 120 hour . Bronchoalveolar lavage ( BAL ) blood sample assess randomization 48 hour , order measure tumor necrosis factor-alpha ( TNFα ) , interleukin ( IL ) -1β , IL-6 , IL-8 sRAGE level . Duplicate assay perform Multiplex ( TNFα/interleukins ) ELISA ( sRAGE ) . During 48-hour treatment period , bispectral index ( BIS® ) value range 40 50 targeted neuromuscular block agent ( cisatracurium ) administer group . Protective ventilation strategy apply , well guideline recommendation management ICU patient ARDS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Patients criterion moderate severe ARDS since less 24 hour ( Informed consent Suspected proven intracranial hypertension Midazolam , sevoflurane cisatracurium allergy Medical history malignant hyperthermia Severe liver failure Chemotherapy treatment last month Severe neutropenia ( &lt; 0.5 G/l )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute respiratory distress syndrome ( ARDS )</keyword>
	<keyword>Sevoflurane</keyword>
	<keyword>Mechanical ventilation</keyword>
	<keyword>Intensive Care Unit ( ICU )</keyword>
	<keyword>Prospective study</keyword>
	<keyword>Lung injury</keyword>
	<keyword>Gas exchange</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Receptor advance glycation end-produts ( RAGE )</keyword>
	<keyword>sRAGE</keyword>
</DOC>